Has Adam Horvit, MD received payments from drug or device companies?

Yes. Drug and device makers reported $308,903 in general payments to Adam Horvit, MD across 294 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Adam Horvit, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Adam Horvit, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Adam Horvit, MD

Neurology · Round Rock, TXNPI 1578590105

Payments from drug & device makers

$308,903in general payments, 2019–2025

Across 294 payments — averaging $1050.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$249K
Argenx US, Inc.$29K
Novartis$12K
Genentech, Inc.$8K
Takeda Pharmaceuticals U.S.A., Inc.$8K
Genentech USA, Inc.$408
plus $3K from 35 others

$1,046in research payments, 2019–2025

Across 4 payments — averaging $261.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$1K

What the payments were for

Speaking & faculty fees$63,84586%
Travel & lodging$4,2576%
Food & beverage$6,3689%
Education$280%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	74	$248,514
Argenx US, Inc.	33	$29,123
Novartis	6	$12,088
Genentech, Inc.	6	$7,953
Takeda Pharmaceuticals U.S.A., Inc.	3	$7,750
Genentech USA, Inc.	32	$408
Octapharma USA, Inc.	12	$374
AbbVie(2 entities)	15	$290
EDW Pharma, Inc.	1	$288
Acadia Pharmaceuticals Inc	17	$271
Biogen	7	$211
Teva Pharmaceuticals USA, Inc.	11	$181
Pfizer	20	$177
Tanabe Pharma America, Inc.	7	$140
Akcea Therapeutics, Inc.	2	$133
UCB, Inc.	3	$101
Sanofi	4	$85
Amgen	4	$82
EMD Serono, Inc.	6	$78
SK Life Science, Inc.	3	$63
Grifols USA, LLC	3	$60
Averitas Pharma Inc.	2	$50
Lilly USA, LLC	3	$50
Lundbeck LLC	1	$48
Abbott	2	$37
Microtransponder, Inc.	1	$35
Amylyx Pharmaceuticals, Inc.	1	$32
MDD US Operations, LLC	2	$31
Alnylam Pharmaceuticals Inc.	1	$27
Eisai Inc.	1	$24
Catalyst Pharmaceuticals, Inc.	1	$23
ANI Pharmaceuticals, Inc.	1	$22
Greenwich Biosciences, Inc.	1	$21
Neurocrine Biosciences, Inc.	1	$20
Amicus Therapeutics, Inc.	1	$20
Johnson & Johnson	1	$19
Jazz Pharmaceuticals Inc.	1	$18
Life Molecular Imaging Ltd	1	$17
Novo Nordisk	1	$15
Shire North American Group Inc	1	$15
Avanir Pharmaceuticals, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$308,903 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024

$1,563,952

Medicare patients

496

Services billed

18,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Radicava OrsEdaravone	19	$266,765
Gabapentin	466	$9,538
Rivastigmine	45	$6,854
Tramadol Hcl ErTramadol Hcl	25	$4,064
Pyridostigmine Bromide	87	$3,971
Pregabalin	178	$3,922
Duloxetine Hcl	192	$3,823
Mycophenolate Mofetil	43	$3,021
Donepezil Hcl	194	$2,019
Levetiracetam	67	$1,671
Memantine Hcl	121	$1,615
Ropinirole Hcl	37	$1,080
Oxcarbazepine	15	$1,032
Memantine Hcl ErMemantine Hcl	15	$985
Prednisone	106	$707

Paid to pharmacies, not to this prescriber.

Other neurology in Round Rock

Elizabeth PeckhamRound Rock$5.4M
Ann BassSan Antonio$12.3M
Kandasami SenthilkumarBeaumont$7.6M
Bharathy SundaramSherman$7.2M
Bhupesh DiheniaLubbock$6.9M
Jamshid LotfiHouston$6M
Nazanin MajdHouston$5.9M
Aziz ShaibaniHouston$5.5M
Susan IannacconeDallas$5.1M
Benjamin GreenbergDallas$4.6M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →